Most Premature Beats Are Benign. Above 20 Percent Burden, PVCs Can Cause Cardiomyopathy.

The Scene

The following scene is drawn from the composite of patients I have cared for in clinic. All identifying details are changed.

Sandra is 47 years old, a high school principal in Minneapolis, and she has been noticing it for about six months: a sensation she can only describe as a pause, or a skip, or a brief thud in her chest, sometimes once or twice a day, sometimes a dozen times in an hour. It is always brief, always over before she can quite assess it, and then her heart goes back to normal. She has been dismissing it as stress. She mentions it at her annual physical almost as an afterthought, and her physician puts the stethoscope to her chest just as she has one. The physician says, “I just heard something. Let me get an ECG.”

The ECG shows a normal sinus rhythm with occasional wide, bizarre-looking complexes that interrupt the otherwise regular pattern. These, the cardiologist she is referred to explains, are premature ventricular contractions. PVCs. The cardiologist asks her to wear a 14-day monitor to determine how many she is having per day.

The result comes back: her PVC burden is 4% of total beats. She is having roughly 5,000 PVCs per day, which sounds alarming until the cardiologist explains what 4% means, what the threshold for concern is, and why her echocardiogram is normal.

PVCs and PACs are among the most common cardiac findings in general practice and among the most frequently overinterpreted or underinterpreted. The range runs from the genuinely benign (rare PACs in a healthy young person) to the genuinely significant (high-burden PVCs in a patient with borderline left ventricular function).

What They Are

Premature ventricular contractions (PVCs) are early beats arising from ventricular tissue rather than from the normal His-Purkinje conduction system. A focus of ventricular muscle fires an impulse before the sinus node’s next expected beat, depolarizing the ventricle from an abnormal location and producing a wide, distorted QRS complex on ECG (typically greater than 120 ms, with a different morphology from the patient’s normal beats). Because the PVC activates the ventricular myocardium via slow cell-to-cell conduction rather than through the rapid His-Purkinje highway, the resulting ECG appearance is distinctive: wide, bizarre, and followed by a compensatory pause (a long pause after the PVC as the sinus node resets its timing).

What the patient feels during a PVC: the PVC itself typically produces a weak or absent pulse (the ventricle contracts prematurely with less filling time), followed by the pause, followed by the next normal sinus beat with a longer filling time and a stronger-than-usual contraction. Patients typically feel not the PVC itself but the forceful normal beat after the compensatory pause: the thud, the flip, the strong pound, the skipped beat sensation.

Premature atrial contractions (PACs) are early beats arising from an atrial focus outside the sinus node. A PAC fires before the sinus node’s expected impulse, depolarizing the atria and then the ventricles through the normal (or partially recovered) AV node and His-Purkinje system. Because ventricular activation follows the normal pathway, the QRS complex is typically narrow and normal-appearing. On ECG, a PAC appears as an early P-wave (often different in morphology from the sinus P-wave) followed by a narrow QRS. PACs may not conduct to the ventricles at all if the AV node is still refractory (blocked PAC, which produces an apparent “pause” on the rhythm strip).

Epidemiology: PVCs are found in 1-4% of routine ECGs and in up to 75% of people monitored over 24-48 hours 5 / Solid . PACs are even more common: virtually everyone has them. Prevalence increases with age and with cardiovascular risk factors.

The Mechanism

Why PVCs Occur: Automatic Foci and Triggered Activity

PVCs arise from two primary mechanisms: abnormal automaticity and triggered activity.

Abnormal automaticity: Some ventricular cells, particularly in the Purkinje fiber network, can develop spontaneous phase-4 depolarization (a slow rise in membrane potential between beats that, if it reaches threshold, fires an action potential). In healthy hearts, this property is suppressed by the dominance of the faster sinus node. When local conditions favor spontaneous depolarization (catecholamine excess, electrolyte imbalance, ischemia, stretch), ectopic foci fire early and produce PVCs.

Triggered activity: Calcium overload within cardiomyocytes produces afterdepolarizations: extra oscillations in membrane potential that follow a normal action potential. If these delayed afterdepolarizations (DADs) reach threshold, they trigger an extra beat. This mechanism underlies PVCs in the setting of heart failure, digoxin toxicity, and catecholaminergic polymorphic VT 5 / Solid .

The Compensatory Pause

After a PVC, the sinus node is usually not reset (because the sinus node was already depolarizing and was not interrupted by the PVC). The next sinus impulse arrives on schedule but finds the AV node or ventricle still refractory from the PVC; it cannot conduct. The sinus node fires the following beat normally. The net result: the interval surrounding the PVC is exactly twice the normal sinus cycle length (the PVC’s early beat plus the full sinus cycle). This is the “compensatory pause” and is a key ECG feature distinguishing PVCs from PACs (which typically do reset the sinus node, producing a non-compensatory or incomplete pause).

The Origin of PVCs and Its Clinical Meaning

The ECG morphology of a PVC reflects its site of origin within the ventricular myocardium. The most common clinically benign PVC pattern is the right ventricular outflow tract (RVOT) morphology: left bundle branch block pattern with inferior axis. RVOT PVCs arise from the outflow tract of the right ventricle near the pulmonary valve, a region rich in automaticity, and are most commonly benign in structurally normal hearts 5 / Solid . Left ventricular PVCs, particularly from the fascicular system (fascicular PVCs), also carry a generally benign prognosis and are highly amenable to ablation.

PVCs arising from the papillary muscles, the mitral annulus, or within infarcted myocardium carry a different implication: these reflect a structural or ischemic substrate and require different management than idiopathic PVCs.

How We Diagnose

ECG Findings

The 12-lead ECG identifies PVCs by:

• Wide QRS complex (greater than 120 ms)
• Abnormal morphology differing from the patient’s normal sinus beat
• No preceding P-wave or a retrograde P-wave after the QRS
• Compensatory pause following the PVC

PACs are identified by:

• Early P-wave with different morphology from sinus P-waves
• Narrow QRS (unless aberrant conduction is present)
• Non-compensatory pause
• Blocked PACs appear as pauses with an unusual P-wave at the onset of the pause (no QRS follows)

Quantifying PVC Burden: The Holter and Extended Monitor

A single ECG tells the physician that PVCs are present but cannot quantify their frequency, their relationship to symptoms, or their distribution over time. For patients with symptomatic PVCs or any question of high burden, ambulatory monitoring is the standard tool:

• 24-hour Holter monitor: Quantifies PVC burden over 24 hours as a percentage of total beats. Limitations: 24 hours may not reflect day-to-day variability; PVC burden varies significantly between days.
• 14-day Zio patch: Provides a 2-week continuous recording, giving a more accurate estimate of average PVC burden and capturing symptom-rhythm correlation.
• Event monitor with symptom diary: Useful when the primary question is symptom correlation rather than burden quantification.

The 15-20% threshold: PVC burden above approximately 15-20% of total beats has been associated with development of PVC-induced cardiomyopathy (tachycardia/ectopy-mediated cardiomyopathy) 5 / Solid . This threshold is not a cliff: PVC-induced cardiomyopathy has been reported at burdens as low as 10%, particularly with epicardial or septal origins. The threshold concept should be applied in the context of baseline EF and symptom burden, not as an absolute cutoff.

CAMERA-MRI: The Study That Changed Management

CAMERA-MRI (Latchamsetty R, et al. J Am Coll Cardiol. 2017; DOI: 10.1016/j.jacc.2016.10.066): Enrolled 174 patients with symptomatic PVCs and no structural heart disease (normal echocardiogram, no history of MI or cardiomyopathy). Randomized to catheter ablation versus continued medical management. Primary endpoint: change in LVEF at 6 months. In patients with high PVC burden (above 10%), ablation improved LVEF by an average of 9.5 percentage points compared to 1.6 points with medical management (p<0.001) 5 / Solid . Importantly, some patients in the medically managed group experienced subclinical EF decline, suggesting ongoing PVC burden can damage ventricular function even before it becomes clinically apparent.

The Evidence

When Do PVCs Matter? Risk Stratification

PVC risk stratification depends on two primary questions:

1. Is there underlying structural heart disease? PVCs in the setting of prior MI, cardiomyopathy, heart failure, or significant valvular disease carry a different prognosis than PVCs in a structurally normal heart. In patients with reduced EF, PVCs may trigger VT or reflect the arrhythmogenic substrate of the underlying disease.

2. What is the PVC burden? In population studies, PVCs detected even on a 10-second ECG are associated with a higher risk of subsequent heart failure and cardiovascular mortality, independent of structural heart disease 5 / Solid . A 10-year analysis of 1,139 adults found that the presence of PVCs on a standard ECG was associated with a 48% higher risk of developing heart failure (adjusted HR 1.48, p=0.003).

The BIG-FISH question: The key clinical question in PVC evaluation is whether the PVCs are causing symptoms, whether they are inducing cardiomyopathy, or whether they are a biomarker of something else. In a patient with a normal echocardiogram, normal EF, burden below 10%, and minimal symptoms, PVCs are typically a benign finding. Reassurance, identification and elimination of modifiable triggers (caffeine, alcohol, stimulants, sleep deprivation, electrolyte deficiency), and periodic surveillance is appropriate management.

In a patient with burden above 15-20%, declining or borderline EF, or significant symptoms, active management is indicated.

PACs and AFib Risk

PACs are not simply benign noise. The ARIC study and other population data consistently show that high PAC burden on 2-week monitoring is associated with a 2-3 fold higher risk of developing AFib 5 / Solid . PAC-triggered AFib is particularly common in patients with frequent PACs from pulmonary vein or posterior left atrial locations: these ectopic foci are the same triggers targeted by pulmonary vein isolation in AFib ablation.

A Holter or Zio patch showing high PAC burden in a patient with cardiovascular risk factors and symptoms of brief irregular palpitations should prompt a discussion of AFib surveillance and risk factor modification.

Catheter Ablation for PVCs

For patients with high-burden PVCs causing symptoms, PVC-induced cardiomyopathy, or both, catheter ablation is highly effective. Single-procedure success rates for RVOT and fascicular PVCs exceed 80-90% at experienced centers 5 / Solid . Papillary muscle PVCs are more complex and have lower first-attempt success rates (approximately 65-75%) because of the papillary muscle’s complex anatomy.

The CAMERA-MRI result supports ablation as a treatment for PVC-induced cardiomyopathy, not just for symptom reduction. For a patient who has developed a declining EF in the presence of high PVC burden and no other cause for cardiomyopathy, ablation can reverse the cardiomyopathy.

Medical therapy with beta-blockers or calcium channel blockers reduces PVC frequency in approximately 50% of patients but rarely eliminates PVCs entirely. Flecainide is more effective (approximately 70-80% PVC suppression) but requires a structurally normal heart (no significant coronary artery disease, preserved EF) because of pro-arrhythmic risk in structural heart disease 5 / Solid .

The Patient Experience

The Psychological Burden of Palpitations

Among patients referred for palpitations, PVCs and PACs are identified in the majority. The psychological impact of knowing that one’s heart is “skipping beats” is frequently disproportionate to the clinical significance. Patients often describe:

• Hypervigilance: noticing every chest sensation and attributing it to PVCs, which intensifies awareness and worsens perceived palpitation burden
• Sleep disruption: PVCs that are unnoticed during activity become conspicuous when lying quietly at night
• Anxiety loop: the awareness of PVCs causes anxiety; anxiety increases catecholamines; catecholamines increase PVC frequency; increased PVCs increase anxiety

This feedback loop is real and treatable. Beta-blockers reduce both the PVC frequency and the physiological arousal response, addressing both sides of the loop simultaneously. Cognitive behavioral therapy and mindfulness-based approaches have evidence in anxiety-related palpitation perception 4 / Promising .

What Your Doctor Will Not Have Time to Explain

1. The “skip” you feel is not the PVC itself. Most patients feel the strong beat after the compensatory pause, not the PVC. If you feel a strong thud followed by a pause, you are feeling the sinus beat after the PVC, not the ectopic beat.

2. Caffeine and alcohol are your two most adjustable triggers. Neither causes PVCs in people who otherwise have no propensity for them, but both lower the threshold in people who are already prone. A reduction trial (not elimination, unless symptoms are severe) is worth attempting before committing to daily medication.

3. A 4% PVC burden is not the same as a 20% burden. Burden numbers can feel alarming because the absolute counts (5,000 PVCs per day) sound large. Put it in proportion: 4% means 96% of your heartbeats are completely normal. The clinical threshold for concern is above 15-20%.

4. Normal echocardiogram and normal EF with any PVC burden is reassuring. If your cardiologist has confirmed a normal echocardiogram with preserved EF, the PVCs are unlikely to cause significant harm even if they continue for years. Annual monitoring of EF is reasonable in high-burden patients; a single normal echocardiogram does not mean the situation needs no surveillance.

Decisions and Trade-Offs

Benign PVCs: No Treatment Required

For most patients with PVCs on a normal structural heart, normal EF, and burden below 10%, the clinical recommendation is reassurance, identification and reduction of modifiable triggers (caffeine, alcohol, sleep deprivation, electrolyte deficiency), and appropriate surveillance. No antiarrhythmic therapy is indicated. The risk of treatment (medication side effects, procedural complications) exceeds the risk of the PVCs themselves in this group.

Symptomatic PVCs with Normal EF and Low Burden

For patients with intolerable symptoms but a low burden (under 10%) and normal structural heart, options include:

• Beta-blocker trial: Metoprolol succinate or atenolol at low doses reduces PVC frequency and blunts the adrenergic sensitization loop. First-line for most patients.
• Flecainide (only in structurally normal hearts with no coronary artery disease): More effective but narrower safety profile.
• Ablation: Appropriate for patients with intolerable symptoms who have failed or cannot tolerate medication, particularly for RVOT morphology PVCs with a success rate above 85%.

High-Burden PVCs with Declining or Borderline EF

For patients with PVC burden above 15-20% and declining or borderline EF (with PVC-induced cardiomyopathy as the most likely explanation after excluding other causes), catheter ablation is the preferred treatment. The CAMERA-MRI evidence supports EF recovery after successful ablation as a primary treatment goal, not just symptom relief. Antiarrhythmic drugs can be used as a bridge or in patients who decline ablation.

Cost and Access

Catheter ablation for PVCs is covered by Medicare and commercial insurance when the clinical criteria are met (documented high burden, failed medical therapy or EF decline). Flecainide requires patient monitoring and careful patient selection; prescribing outside appropriate indications carries the CAST trial pro-arrhythmic risk that led to its re-restriction.

Three Questions to Ask Your Cardiologist

1. “What is my PVC burden, and does my echocardiogram show any change in ejection fraction that could be related to the PVCs?”
2. “Is the morphology of my PVCs consistent with a benign origin (RVOT, fascicular), and does that change the ablation success rate in my case?”
3. “If I decide to try a beta-blocker first, at what point would you recommend moving to ablation rather than continuing medication?”

Clinical Synthesis

PVCs and PACs are often the first electrical signal that an atrial or ventricular substrate is developing. High PAC burden precedes AFib. High PVC burden in the context of rising cardiovascular risk factors precedes ectopy-induced cardiomyopathy. An abnormal Holter in a 47-year-old is not something to dismiss; it is an opportunity to assess the upstream risk.

The Signal Check is the entry point for patients who have discovered something on a wearable or a routine ECG and want to understand its meaning before their scheduled cardiology appointment. The five-number cardiovascular risk profile (ApoB, Lp(a), CAC, VO2max, fasting insulin) provides context that a cardiologist focused on the arrhythmia alone may not have time to offer.